Univariate and multivariate analyses of factors influencing relapse among patients transplanted in CR1, according to donor type
| Covariates . | Related (n = 310) . | Unrelated (n = 331) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N . | Univariate . | Multivariate . | N . | Univariate . | Multivariate . | |||||
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |||
| WBC count at diagnosis | ||||||||||
| < 30 000/μL | 224 | 1.00 | — | 230 | 1.00 | — | ||||
| 30 000/μL or more at diagnosis | 86 | 0.88 (0.52-1.47) | .62 | — | 101 | 1.11 (0.62-1.98) | .72 | — | ||
| Lineage | ||||||||||
| B | 218 | 1.00 | — | 203 | 1.00 | — | ||||
| T | 50 | 0.54 (0.22-1.37) | .09 | — | 54 | 1.31 (0.57-3.02) | .62 | — | ||
| Other | 42 | 1.21 (0.66-2.21) | .54 | — | 74 | 1.06 (0.53-2.11) | .87 | — | ||
| Karyotype | ||||||||||
| Normal | 193 | 1.00 | — | 208 | 1.00 | — | ||||
| t(4;11) or t(1;19) | 21 | 0.64 (0.19-2.12) | .36 | — | 11 | 1.97 (0.46-8.35) | .91 | — | ||
| Other (no t(9;22)) | 96 | 1.11 (0.68-1.82) | .67 | — | 112 | 2.15 (1.24-3.73) | .01 | 2.15 (1.24-3.73) | .01 | |
| JALSG risk stratification | ||||||||||
| Low | 39 | 1.00 | — | 45 | 1.00 | — | ||||
| Intermediate | 163 | 0.96 (0.59-1.55) | .87 | — | 192 | 1.04 (0.57-1.91) | .90 | — | ||
| High | 108 | 0.81 (0.35-1.84) | .61 | — | 94 | 1.04 (0.43-2.52) | .94 | — | ||
| Age at allo-SCT | ||||||||||
| < 45 y old | 255 | 1.00 | — | 281 | 1.00 | — | ||||
| 45 y old or older at allo-SCT | 55 | 0.82 (0.41-1.64) | .57 | — | 50 | 0.74 (0.42-1.32) | .08 | — | ||
| HLA | ||||||||||
| Match | 285 | 1.00 | — | 192 | 1.00 | — | ||||
| Mismatch | 25 | 0.82 (0.33-2.02) | .66 | — | 139 | 0.74 (0.42-1.32) | .31 | — | ||
| Stem cell source* | ||||||||||
| Bone marrow | 212 | 1.00 | — | — | ||||||
| Peripheral blood | 98 | 1.07 (0.65-1.76) | .79 | — | — | |||||
| Time from diagnosis to allo-SCT | ||||||||||
| 6 mo or longer | 169 | 1.00 | — | 23 | 1.00 | — | ||||
| < 6 mo | 141 | 1.68 (1.05-2.69) | .03 | 1.68 (1.05-2.69) | .03 | 308 | 0.47 (0.11-1.92) | .29 | — | |
| < 10 mo | 278 | 1.00 | — | 166 | 1.00 | — | ||||
| 10 mo or longer | 32 | 0.49 (0.18-1.34) | .16 | — | 165 | 0.92 (0.54-1.58) | .76 | — | ||
| Preparative regimen | ||||||||||
| Non-TBI regimens | 25 | 1.00 | — | 12 | 1.00 | — | ||||
| TBI regimens | 285 | 0.62 (0.31-1.25) | .18 | — | 319 | 0,47 (0.15-1.52) | .21 | — | ||
| GVHD prophylaxis | ||||||||||
| Cyclosporine A with or without other | 283 | 1.00 | — | 171 | 1.00 | — | ||||
| Tacrolimus with or without other | 27 | 1.62 (0.81-3.26) | .18 | — | 160 | 1.39 (0.81-2.38) | .24 | — | ||
| Covariates . | Related (n = 310) . | Unrelated (n = 331) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N . | Univariate . | Multivariate . | N . | Univariate . | Multivariate . | |||||
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |||
| WBC count at diagnosis | ||||||||||
| < 30 000/μL | 224 | 1.00 | — | 230 | 1.00 | — | ||||
| 30 000/μL or more at diagnosis | 86 | 0.88 (0.52-1.47) | .62 | — | 101 | 1.11 (0.62-1.98) | .72 | — | ||
| Lineage | ||||||||||
| B | 218 | 1.00 | — | 203 | 1.00 | — | ||||
| T | 50 | 0.54 (0.22-1.37) | .09 | — | 54 | 1.31 (0.57-3.02) | .62 | — | ||
| Other | 42 | 1.21 (0.66-2.21) | .54 | — | 74 | 1.06 (0.53-2.11) | .87 | — | ||
| Karyotype | ||||||||||
| Normal | 193 | 1.00 | — | 208 | 1.00 | — | ||||
| t(4;11) or t(1;19) | 21 | 0.64 (0.19-2.12) | .36 | — | 11 | 1.97 (0.46-8.35) | .91 | — | ||
| Other (no t(9;22)) | 96 | 1.11 (0.68-1.82) | .67 | — | 112 | 2.15 (1.24-3.73) | .01 | 2.15 (1.24-3.73) | .01 | |
| JALSG risk stratification | ||||||||||
| Low | 39 | 1.00 | — | 45 | 1.00 | — | ||||
| Intermediate | 163 | 0.96 (0.59-1.55) | .87 | — | 192 | 1.04 (0.57-1.91) | .90 | — | ||
| High | 108 | 0.81 (0.35-1.84) | .61 | — | 94 | 1.04 (0.43-2.52) | .94 | — | ||
| Age at allo-SCT | ||||||||||
| < 45 y old | 255 | 1.00 | — | 281 | 1.00 | — | ||||
| 45 y old or older at allo-SCT | 55 | 0.82 (0.41-1.64) | .57 | — | 50 | 0.74 (0.42-1.32) | .08 | — | ||
| HLA | ||||||||||
| Match | 285 | 1.00 | — | 192 | 1.00 | — | ||||
| Mismatch | 25 | 0.82 (0.33-2.02) | .66 | — | 139 | 0.74 (0.42-1.32) | .31 | — | ||
| Stem cell source* | ||||||||||
| Bone marrow | 212 | 1.00 | — | — | ||||||
| Peripheral blood | 98 | 1.07 (0.65-1.76) | .79 | — | — | |||||
| Time from diagnosis to allo-SCT | ||||||||||
| 6 mo or longer | 169 | 1.00 | — | 23 | 1.00 | — | ||||
| < 6 mo | 141 | 1.68 (1.05-2.69) | .03 | 1.68 (1.05-2.69) | .03 | 308 | 0.47 (0.11-1.92) | .29 | — | |
| < 10 mo | 278 | 1.00 | — | 166 | 1.00 | — | ||||
| 10 mo or longer | 32 | 0.49 (0.18-1.34) | .16 | — | 165 | 0.92 (0.54-1.58) | .76 | — | ||
| Preparative regimen | ||||||||||
| Non-TBI regimens | 25 | 1.00 | — | 12 | 1.00 | — | ||||
| TBI regimens | 285 | 0.62 (0.31-1.25) | .18 | — | 319 | 0,47 (0.15-1.52) | .21 | — | ||
| GVHD prophylaxis | ||||||||||
| Cyclosporine A with or without other | 283 | 1.00 | — | 171 | 1.00 | — | ||||
| Tacrolimus with or without other | 27 | 1.62 (0.81-3.26) | .18 | — | 160 | 1.39 (0.81-2.38) | .24 | — | ||
HR indicates hazard ratio; CI, confidence interval; WBC, white blood cell; —, not applicable; and TBI, total body irradiation.
Stem cell source (peripheral blood) was not a significant risk factor for relapse in the multivariate analysis.